ELCC 2017

05–08 May 2017 | Geneva, Switzerland

The 7th European Lung Cancer Conference (ELCC) took place in Geneva, Switzerland on 5-8 May 2017.

The program covered content relevant for medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of lung cancer patients.

ELCC 2017

05–08 May 2017 | Geneva, Switzerland

The 7th European Lung Cancer Conference (ELCC) took place in Geneva, Switzerland on 5-8 May 2017.

The program covered content relevant for medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of lung cancer patients.

Biomarkers are revolutionizing the treatment landscape for NSCLC 0:56
Biomarkers are revolutionizing the treatment landscape for NSCLC
Martin Reck • 5 May 2017
The pathologist in cancer care 2:14
The pathologist in cancer care
Keith Kerr • 6 May 2017
PD-L1 agents in the treatment of NSCLC 1:50
PD-L1 agents in the treatment of NSCLC
David Gandara • 5 May 2017
Targeted therapies for advanced NSCLC 1:24
Targeted therapies for advanced NSCLC
Martin Reck • 5 May 2017
Prof. Martin Reck on ELCC 2017 and what makes it a unique lung cancer conference 2:06
Prof. Martin Reck on ELCC 2017 and what makes it a unique lung cancer conference
Martin Reck • 5 May 2017
NSCLC: the increasing need for PD-L1 testing 2:49
NSCLC: the increasing need for PD-L1 testing
Keith Kerr • 5 May 2017
Current treatment options for squamous cell lung cancer 2:46
Current treatment options for squamous cell lung cancer
David Gandara • 5 May 2017
Lung cancer: from immunotherapy to precision medicine 2:38
Lung cancer: from immunotherapy to precision medicine
David Carbone • 5 May 2017
Data update in advanced stage NSCLC 1:41
Data update in advanced stage NSCLC
Solange Peters • 6 May 2017
Maximizing treatment benefits in NSCLC 1:40
Maximizing treatment benefits in NSCLC
Nicolas Girard • 6 May 2017
ESMO guidelines for thymic cancer management 1:52
ESMO guidelines for thymic cancer management
Nicolas Girard • 5 May 2017
The genetic landscape of lung cancer 1:00
The genetic landscape of lung cancer
Martin Reck • 5 May 2017
NSCLC: identifying patients most likely to relapse 1:35
NSCLC: identifying patients most likely to relapse
Charles Swanton • 5 May 2017
Genetic evolution of NSCLC 2:09
Genetic evolution of NSCLC
Charles Swanton • 5 May 2017
Increasing treatment options for NSCLC 2:07
Increasing treatment options for NSCLC
David Gandara • 5 May 2017
Benefits of targeted therapeutics in Lung Cancer 2:09
Benefits of targeted therapeutics in Lung Cancer
David Carbone • 5 May 2017
The content of VJOncology is intended for healthcare professionals